{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:26:19Z","timestamp":1788582379727,"version":"build-2803163510"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["CFTY720DDE08T"],"award-info":[{"award-number":["CFTY720DDE08T"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13311-021-01078-7","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T13:03:27Z","timestamp":1625835807000},"page":"1783-1797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells"],"prefix":"10.1016","volume":"18","author":[{"given":"Svenja C.","family":"Schwichtenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wisgalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schroeder-Castagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Alvarez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schlickeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bellmann-Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Dieter","family":"Wernecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-351X","authenticated-orcid":false,"given":"Carmen","family":"Infante-Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01078-7_bib1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"The Lancet"},{"key":"10.1007\/s13311-021-01078-7_bib2","first-page":"229","article-title":"The Histology of Disseminated Sclerosis","volume":"17","author":"Dawson","year":"1916","journal-title":"Edinb Med J"},{"key":"10.1007\/s13311-021-01078-7_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01078-7_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","article-title":"Pathology of demyelinating diseases","volume":"7","author":"Popescu","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1007\/s13311-021-01078-7_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nri2550","article-title":"Autoimmune T cell responses in the central nervous system","volume":"9","author":"Goverman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01078-7_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0036-1579739","article-title":"Immunology of Multiple Sclerosis","volume":"36","author":"Sospedra","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1007\/s13311-021-01078-7_bib8","doi-asserted-by":"crossref","unstructured":"Signori A, Sacc\u00e0 F, Lanzillo R, et al. Cladribine vs other drugs in MS: Merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm 2020;7:e878.","DOI":"10.1212\/NXI.0000000000000878"},{"key":"10.1007\/s13311-021-01078-7_bib9","doi-asserted-by":"crossref","unstructured":"Diem L, Daponte A, Findling O, et al. Dimethyl fumarate vs fingolimod following different pretreatments. Neurol Neuroimmunol Neuroinflamm 2020;7:e660.","DOI":"10.1212\/NXI.0000000000000660"},{"key":"10.1007\/s13311-021-01078-7_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01078-7_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01078-7_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01078-7_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13167-019-00192-z","article-title":"Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials","volume":"10","author":"Gehr","year":"2019","journal-title":"EPMA J"},{"key":"10.1007\/s13311-021-01078-7_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01078-7_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.devcel.2012.08.005","article-title":"The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2","volume":"23","author":"Gaengel","year":"2012","journal-title":"Dev Cell"},{"key":"10.1007\/s13311-021-01078-7_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.devcel.2012.07.015","article-title":"Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development","volume":"23","author":"Jung","year":"2012","journal-title":"Dev Cell"},{"key":"10.1007\/s13311-021-01078-7_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0092-8674(00)81661-X","article-title":"Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate","volume":"99","author":"Lee","year":"1999","journal-title":"Cell"},{"key":"10.1007\/s13311-021-01078-7_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/cvr\/cvp064","article-title":"Sphingosine-1-phosphate and modulation of vascular tone","volume":"82","author":"Igarashi","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1007\/s13311-021-01078-7_bib19","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1007\/s13311-021-01078-7_bib20","unstructured":"EuropeanMedicinesAgency. Annex 1: Summary of product characteristics. In: European Medicines Agency [online]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf. Accessed October 30, 2020."},{"key":"10.1007\/s13311-021-01078-7_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-021-01078-7_bib22","doi-asserted-by":"crossref","unstructured":"Cellerino M, Ivaldi F, Pardini M, et al. Impact of treatment on cellular immunophenotype in MS. A cross-sectional study Neurol Neuroimmunol Neuroinflamm 2020;7:e693.","DOI":"10.1212\/NXI.0000000000000693"},{"key":"10.1007\/s13311-021-01078-7_bib23","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1084\/jem.20090525","article-title":"T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow","volume":"206","author":"Jenne","year":"2009","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01078-7_bib24","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2019.00217","article-title":"Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells","volume":"10","author":"Eken","year":"2019","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib26","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.136.12.4480","article-title":"The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes","volume":"136","author":"Lanier","year":"1986","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nri3065","article-title":"Organ-specific features of natural killer cells","volume":"11","author":"Shi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12026-013-8477-9","article-title":"Organ-specific phenotypic and functional features of NK cells in humans","volume":"58","author":"Sharma","year":"2014","journal-title":"Immunol Res"},{"key":"10.1007\/s13311-021-01078-7_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jneuroim.2012.08.009","article-title":"Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation","volume":"254","author":"Hamann","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib30","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/brain\/awn132","article-title":"Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis?","volume":"131","author":"L\u00fcnemann","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01078-7_bib31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2119\/molmed.2009.00035","article-title":"Regulatory NK-cell functions in inflammation and autoimmunity","volume":"15","author":"L\u00fcnemann","year":"2009","journal-title":"Mol Med"},{"key":"10.1007\/s13311-021-01078-7_bib32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/1352458518800776","article-title":"Enhancing natural killer cells is beneficial in multiple sclerosis \u2013 Yes","volume":"25","author":"Laroni","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-021-01078-7_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/1352458518799591","article-title":"Enhancing natural killer cells is beneficial in multiple sclerosis - No","volume":"25","author":"Liu","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-021-01078-7_bib34","first-page":"657","article-title":"Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor","volume":"39","author":"Benczur","year":"1980","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0171-2985(82)80003-X","article-title":"Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis","volume":"160","author":"Uchida","year":"1982","journal-title":"Immunobiology"},{"key":"10.1007\/s13311-021-01078-7_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.35.4.597","article-title":"The effect of recombinant alpha 2-interferon on defective natural killer cell activity in multiple sclerosis","volume":"35","author":"Hirsch","year":"1985","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01078-7_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-5728(95)00115-9","article-title":"Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls","volume":"62","author":"Munschauer","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-5728(98)00014-9","article-title":"A role for natural killer cells in the immunopathogenesis of multiple sclerosis","volume":"86","author":"Kastrukoff","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2003.10.001","article-title":"Clinical relapses of multiple sclerosis are associated with \u2018novel\u2019 valleys in natural killer cell functional activity","volume":"145","author":"Kastrukoff","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1096\/fj.05-3832fje","article-title":"Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients","volume":"19","author":"Infante-Duarte","year":"2005","journal-title":"FASEB J"},{"key":"10.1007\/s13311-021-01078-7_bib41","doi-asserted-by":"crossref","first-page":"E2973","DOI":"10.1073\/pnas.1524924113","article-title":"Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation","volume":"113","author":"Gross","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01078-7_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-5728(01)00289-2","article-title":"NK cell-mediated lysis of autologous human oligodendrocytes","volume":"116","author":"Morse","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/immu.200390012","article-title":"Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1\/NKG2D interactions","volume":"33","author":"Backstr\u00f6m","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib44","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1523\/JNEUROSCI.4402-06.2007","article-title":"NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis","volume":"27","author":"Saikali","year":"2007","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01078-7_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-017-1706-x","article-title":"Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis","volume":"134","author":"Lagumersindez-Denis","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-021-01078-7_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2013.10.004","article-title":"Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis","volume":"265","author":"Plantone","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nn.4211","article-title":"Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation","volume":"19","author":"Liu","year":"2016","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-021-01078-7_bib48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1212\/WNL.52.2.351","article-title":"Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B","volume":"52","author":"Kastrukoff","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01078-7_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10072-007-0803-3","article-title":"Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta","volume":"28","author":"Saraste","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-021-01078-7_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2009.08.007","article-title":"Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis","volume":"215","author":"Vandenbark","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01078-7_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.imlet.2019.10.006","article-title":"CD3(-)CD56(+) NK cells display an inflammatory profile in RR-MS patients","volume":"216","author":"Tahrali","year":"2019","journal-title":"Immunol Lett"},{"key":"10.1007\/s13311-021-01078-7_bib52","doi-asserted-by":"crossref","unstructured":"Acar NP, Tuncer A, Ozkazanc D, et al. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-\u03b21 and fingolimod therapy. J Neuroimmunol 2020;347:577353.","DOI":"10.1016\/j.jneuroim.2020.577353"},{"key":"10.1007\/s13311-021-01078-7_bib53","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01078-7_bib54","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/1352458511414755","article-title":"Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis","volume":"17","author":"Sheridan","year":"2011","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-021-01078-7_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0404.2008.00998.x","article-title":"The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis","volume":"118","author":"Jalosinski","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-021-01078-7_bib56","doi-asserted-by":"crossref","unstructured":"Chanvillard C, Millward JM, Lozano M, et al. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One 2012;7:e39625.","DOI":"10.1371\/journal.pone.0039625"},{"key":"10.1007\/s13311-021-01078-7_bib57","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00018-009-8726-1","article-title":"Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate","volume":"66","author":"Sand","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1007\/s13311-021-01078-7_bib58","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/j.1582-4934.2008.00640.x","article-title":"Splenic natural killer cell activity in two models of experimental neurodegenerative diseases","volume":"13","author":"Al-Falahi","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1007\/s13311-021-01078-7_bib59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-021-01078-7_bib60","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4049\/jimmunol.1003823","article-title":"Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients","volume":"187","author":"Johnson","year":"2011","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib61","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01078-7_bib62","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5114\/ceji.2015.54599","article-title":"Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study","volume":"40","author":"Rudnicka","year":"2015","journal-title":"Cent Eur J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib63","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/sji.12347","article-title":"Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade","volume":"82","author":"Mehling","year":"2015","journal-title":"Scand J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib64","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1177\/1352458516679267","article-title":"Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia","volume":"23","author":"Caruana","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1007\/s13311-021-01078-7_bib65","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3389\/fimmu.2018.01693","article-title":"Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study","volume":"9","author":"Moreno-Torres","year":"2018","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib66","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fimmu.2018.01560","article-title":"Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid\u2014Results from the ToFingo Successor Study","volume":"9","author":"Lohmann","year":"2018","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib67","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.3389\/fimmu.2018.02669","article-title":"Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41598-019-57114-2","article-title":"Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis","volume":"10","author":"Ghadiri","year":"2020","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01078-7_bib69","doi-asserted-by":"crossref","unstructured":"Hjorth M, Dandu N, Mellerg\u00e5rd J. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets. PLoS One 2020;15:e0228380.","DOI":"10.1371\/journal.pone.0228380"},{"key":"10.1007\/s13311-021-01078-7_bib70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/cns.12793","article-title":"Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator","volume":"24","author":"Angerer","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1007\/s13311-021-01078-7_bib71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.trim.2006.02.002","article-title":"FTY720 treatment of kidney transplant patients: A differential effect on B cells, na\u00efve T cells, memory T cells and NK cells","volume":"15","author":"Vaessen","year":"2006","journal-title":"Transpl Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01078-7_bib73","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01078-7_bib74","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/0091270011409229","article-title":"Population pharmacokinetics of fingolimod phosphate in healthy participants","volume":"52","author":"Wu","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1007\/s13311-021-01078-7_bib75","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"10.1007\/s13311-021-01078-7_bib76","unstructured":"Brunner E, Domhof S, Langer F. Nonparametric Analysis of Longitudinal Data in Factorial Experiments: Wiley; 2002."},{"key":"10.1007\/s13311-021-01078-7_bib77","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01078-7_bib78","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood-2009-04-215491","article-title":"CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets","volume":"115","author":"Yu","year":"2010","journal-title":"Blood"},{"key":"10.1007\/s13311-021-01078-7_bib79","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood"},{"key":"10.1007\/s13311-021-01078-7_bib80","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/eji.201646632","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies","volume":"47","author":"Cossarizza","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib81","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"10.1007\/s13311-021-01078-7_bib82","doi-asserted-by":"crossref","unstructured":"Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037\u20135044.","DOI":"10.4049\/jimmunol.160.10.5037"},{"key":"10.1007\/s13311-021-01078-7_bib83","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.4049\/jimmunol.177.11.7833","article-title":"Evidence for NK Cell Subsets Based on Chemokine Receptor Expression","volume":"177","author":"Berahovich","year":"2006","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib84","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.166.11.6477","article-title":"Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire","volume":"166","author":"Campbell","year":"2001","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib85","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","article-title":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell\u2013derived IL-2: a potential new link between adaptive and innate immunity","volume":"101","author":"Fehniger","year":"2003","journal-title":"Blood"},{"key":"10.1007\/s13311-021-01078-7_bib86","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2567.2011.03409.x","article-title":"Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells","volume":"133","author":"Hamann","year":"2011","journal-title":"Immunology"},{"key":"10.1007\/s13311-021-01078-7_bib87","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/bloodadvances.2018030676","article-title":"Human peripheral blood DNAM-1(neg) NK cells are a terminally differentiated subset with limited effector functions","volume":"3","author":"Stannard","year":"2019","journal-title":"Blood Adv"},{"key":"10.1007\/s13311-021-01078-7_bib88","doi-asserted-by":"crossref","unstructured":"Alvarez M, Simonetta F, Baker J, et al. Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. JCI Insight 2019;4:e127729.","DOI":"10.1172\/jci.insight.127729"},{"key":"10.1007\/s13311-021-01078-7_bib89","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood-2003-05-1716","article-title":"The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46","volume":"103","author":"Arnon","year":"2004","journal-title":"Blood"},{"key":"10.1007\/s13311-021-01078-7_bib90","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/35059110","article-title":"Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells","volume":"409","author":"Mandelboim","year":"2001","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01078-7_bib91","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/JVI.00211-09","article-title":"Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase","volume":"83","author":"Jarahian","year":"2009","journal-title":"J Virol"},{"key":"10.1007\/s13311-021-01078-7_bib92","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/eji.201646756","article-title":"NK-cell receptors NKp46 and NCR1 control human metapneumovirus infection","volume":"47","author":"Diab","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2249.2007.03555.x","article-title":"Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells","volume":"151","author":"Airas","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib94","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/eji.200636290","article-title":"NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion","volume":"36","author":"Morandi","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib95","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.20051474","article-title":"Natural killer cell behavior in lymph nodes revealed by static and real-time imaging","volume":"203","author":"Baj\u00e9noff","year":"2006","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01078-7_bib96","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e3181cd872d","article-title":"IL-7 enhances survival of human CD56bright NK cells","volume":"33","author":"Michaud","year":"2010","journal-title":"J Immunother"},{"key":"10.1007\/s13311-021-01078-7_bib97","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.celrep.2016.05.095","article-title":"NKp80 Defines a Critical Step during Human Natural Killer Cell Development","volume":"16","author":"Freud","year":"2016","journal-title":"Cell Rep"},{"key":"10.1007\/s13311-021-01078-7_bib98","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.immuni.2005.01.013","article-title":"A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer Cells","volume":"22","author":"Freud","year":"2005","journal-title":"Immunity"},{"key":"10.1007\/s13311-021-01078-7_bib99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0047-6374(97)00045-6","article-title":"Senescence and cytokines modulate the NK cell expression","volume":"96","author":"Krishnaraj","year":"1997","journal-title":"Mech Ageing Dev"},{"key":"10.1007\/s13311-021-01078-7_bib100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.humimm.2011.01.009","article-title":"Age-related changes in natural killer cell receptors from childhood through old age","volume":"72","author":"Almeida-Oliveira","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib101","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.mad.2005.01.004","article-title":"Reciprocal age related change in natural killer cell receptors for MHC class I","volume":"126","author":"Lutz","year":"2005","journal-title":"Mech Ageing Dev"},{"key":"10.1007\/s13311-021-01078-7_bib102","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1474-9726.2012.00839.x","article-title":"Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity","volume":"11","author":"Hazeldine","year":"2012","journal-title":"Aging Cell"},{"key":"10.1007\/s13311-021-01078-7_bib103","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.humimm.2010.03.014","article-title":"Variation of human natural killer cell phenotypes with age: Identification of a unique KLRG1-negative subset","volume":"71","author":"Hayhoe","year":"2010","journal-title":"Hum Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib104","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/icb.2011.15","article-title":"Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients","volume":"90","author":"Sanchez-Correa","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1007\/s13311-021-01078-7_bib105","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/intimm\/10.7.981","article-title":"Age-dependent decreases of NK cell phosphoinositide turnover during spontaneous but not Fc-mediated cytolytic activity","volume":"10","author":"Mariani","year":"1998","journal-title":"Int Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib106","first-page":"340","article-title":"Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing","volume":"68","author":"Facchini","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01078-7_bib107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0024-3205(91)90403-X","article-title":"Persistently low natural killer cell activity, age, and environmental stress as predictors of infectious morbidity","volume":"48","author":"Levy","year":"1991","journal-title":"Life Sci"},{"key":"10.1007\/s13311-021-01078-7_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01078-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:40:47Z","timestamp":1761806447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1878747923007717"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01078-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01078-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}